Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population - A candidate gene approach

International Journal of Cancer

Volumn 125, Issue 8, 2009, Pages 1851-1858

  Castro, Felipe A ^a,b   Haimila, Katri ^c   Sareneva, Inna ^c   Schmitt, Markus ^a   Lorenzo, Justo ^a   Kunkel, Nelli ^a   Kumar, Rajiv ^a   Försti, Asta ^a,d   Kjellberg, Lennart ^e   Hallmans, Göran ^e   Lehtinen, Matti ^b   Hemminki, Kari ^a,d   Pawlita, Michael ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF TAMPERE   (Finland)

^c FINNISH RED CROSS BLOOD SERVICE   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

Genetic study; Host factors; HPV; Human papillomavirus; Nested case control study; Polymorphisms

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; LYMPHOTOXIN; PROTEIN P21; PROTEIN P53; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; CCND1 PROTEIN, HUMAN; HLA-DRB1 ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SWEDEN; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; POLYMERASE CHAIN REACTION; RISK FACTOR; UTERINE CERVIX; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGED; CASE-CONTROL STUDIES; CERVIX UTERI; CYCLIN D1; FEMALE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-6; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SWEDEN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 70349262634     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24529     Document Type: Article

References (59)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24(Suppl 3):S3/11-S3/25.
3. Zur HH. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977;78:1-30.
4. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(Suppl 1):S16-S24.
5. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-1171 (Pubitemid 30451948)
6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007;90:1-636.
7. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999;400:29-30.
8. Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: is there a hereditary component? Int J Cancer 1999;82:775-781
9. Hemminki K, Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev 2006;15:1413-1414 (Pubitemid 44125303)
10. Castro FA, Haimila K, Pasanen K, Kaasila M, Patama T, Partanen J, Surcel HM, Pukkala E, Lehtinen M. Geographic distribution of cervical cancer-associated human leucocyte antigens and cervical cancer incidence in Finland. Int J STD AIDS 2007;18:672-679 (Pubitemid 351738897)
11. Hildesheim A, Schiffman M, Scott DR, Marti D, Kissner T, Sherman ME, Glass AG, Manos MM, Lorincz AT, Kurman RJ, Buckland J, Rush BB, et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998;7:1035-1041 (Pubitemid 28514105)
12. Coleman N, Stanley MA. Expression of the myelomonocytic antigens CD36 and L1 by keratinocytes in squamous intraepithelial lesions of the cervix. Hum Pathol 1994;25:73-79 (Pubitemid 24051828)
13. Nogueira de Souza NC, Brenna SM, Campos F, Syrjanen KJ, Baracat EC, Silva ID. Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer 2006;16:1278-1282 (Pubitemid 43886757)
14. Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, Gyllensten UB. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 2007;121:2451-2457
15. Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der SG, de Vries EG, Te Meerman GJ, van der Zee AG. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer 2005;15(Suppl 3):282-290 (Pubitemid 43096595)
16. Su TH, Chang TY, Lee YJ, Chen CK, Liu HF, Chu CC, Lin M, Wang PT, Huang WC, Chen TC, Yang YC. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007;28:1237-1240 (Pubitemid 47062682)
17. Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, Chu TY. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol 2005;99:113-118
18. Niwa Y, Hirose K, Matsuo K, Tajima K, Ikoma Y, Nakanishi T, Nawa A, Kuzuya K, Tamakoshi A, Hamajima N. Lymphotoxin-alpha polymorphism and the risk of cervical cancer in Japanese subjects. Cancer Lett 2005;218:63-68 (Pubitemid 40082702)
19. Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL, Wheeler CM. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis 2005;191:969-976 (Pubitemid 40349814)
20. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002;13:307-316 (Pubitemid 34553511)
21. Pukkala E, Andersen A, Berglund G, Gislefoss R, Gudnason V, Hallmans G, Jellum E, Jousilahti P, Knekt P, Koskela P, Kyyronen PP, Lenner P, et al. Nordic biological specimen banks as basis for studies of cancer causes and control-more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol 2007;46:286-307. (Pubitemid 46625036)
22. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504-512 (Pubitemid 43222244)
23. Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP51 and GP61 primers. J Clin Microbiol 2008;46:1050-1059
24. The International HapMap C. The International HapMap Project. Nature 2003;426:789-796
25. Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A, Lopes C, Medeiros R. Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 2005;160:49-54. (Pubitemid 40798136)
26. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ, Cunha-Filho JS. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-clinicopathological correlation. Gynecol Oncol 2007;105:157-165 (Pubitemid 46441454)
27. Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993;50:15-19. (Pubitemid 23235504)
28. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin- 6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376 (Pubitemid 28467565)
29. Asselbergs FW, Pai JK, Rexrode KM, Hunter DJ, Rimm EB. Effects of lymphotoxin-alpha gene and galectin-2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules and risk of coronary heart disease. Clin Sci (Lond) 2007;112:291-298
30. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Sato H, Hori M, Nakamura Y, Tanaka T. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002;32:650-654 (Pubitemid 35435179)
31. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001;93:817-822
32. Sanjeevi CB, Hjelmstrom P, Hallmans G, Wiklund F, Lenner P, Angstrom T, Dillner J, Lernmark A. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer 1996;68:409-414 (Pubitemid 26414491)
33. Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U. Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer. Hum Mol Genet 2004;13:1951-1958 (Pubitemid 39214342)
34. Cuzick J, Terry G, Ho L, Monaghan J, Lopes A, Clarkson P, Duncan I. Association between high-risk HPV types. HLA DRB1* and. DQB1* alleles and cervical cancer in. British women. Br J Cancer 2000;82:1348-1352 (Pubitemid 30145357)
35. Apple RJ, Becker TM, Wheeler CM, Erlich HA. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J Natl Cancer Inst 1995;87:427-436
36. Maciag PC, Schlecht NF, Souza PS, Franco EL, Villa LL, Petzl-Erler ML. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev 2000;9:1183-1191
37. Gostout BS, Poland GA, Calhoun ES, Sohni YR, Giuntoli RL, McGovern RM, Sloan JA, Cha SS, Persing DH. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 2003;88:326-332
38. Yang YC, Chang TY, Lee YJ, Su TH, Dang CW, Wu CC, Liu HF, Chu CC, Lin M. HLA-DRB1 alleles and cervical squamous cell carcinoma: experimental study and meta-analysis. Hum Immunol 2006;67:331-340 (Pubitemid 43729364)
39. Chan PK, Cheung TH, Lin CK, Siu SS, Yim SF, Lo KW, Cheung JL, Tam AO, Tang JW. Association between HLA-DRB1 polymorphism, high-risk HPV infection and cervical neoplasia in southern Chinese. J Med Virol 2007;79:970-976
40. Madeleine MM, Johnson LG, Smith AG, Hansen JA, Nisperos BB, Li S, Zhao LP, Daling JR, Schwartz SM, Galloway DA. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res 2008;68:3532-3539
41. Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlee F, Roger M, Franco EL. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 2008;122:2820-2826 (Pubitemid 351649329)
42. Ivansson EL, Magnusson JJ, Magnusson PK, Erlich HA, Gyllensten UB. MHC loci affecting cervical cancer risk: distinguishing the effects of HLA-DQB1 and non-HLA genes TNF, LTA, TAP1 and TAP2. Genes Immun 2008.
43. Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der SG, de Vries EG, Te Meerman GJ, van der Zee AG. Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. J Med Genet 2005;42:e49.
44. Araujo Souza PS, Maciag PC, Ribeiro KB, Petzl-Erler ML, Franco EL, Villa LL. Interaction between polymorphisms of the human leukocyte antigen and HPV-16 variants on the risk of invasive cervical cancer. BMC Cancer 2008;8:246.
45. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tommasino M. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 2001;94:711-716 (Pubitemid 33035692)
46. Wang SS, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, Sherman ME, Barnes WA, Greenberg MD, McGowan L, Mortel R, Schwartz PE, et al. Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage. Cancer Epidemiol Biomarkers Prev 2002;11:419-420
47. Jeon YT, Kim JW, Song JH, Park NH, Song YS, Kang SB, Lee HP. Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett 2005;223:259-263
48. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-1011
49. Sherr CJ, Matsushime H, Roussel MF. Regulation of CYL/cyclin D genes by colony-stimulating factor 1. Ciba Found Symp 1992;170:209-219
50. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002;1:226-231
51. Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, Alaoui-Jamali MA. Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene 2004;23:5252-5256 (Pubitemid 38980357)
52. Simen-Kapeu A, La Ruche G, Kataja V, Yliskoski M, Bergeron C, Horo A, Syrjanen K, Saarikoski S, Lehtinen M, Dabis F, Sasco AJ. Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Cote d'Ivoire and Finland) with different tobacco exposure. Cancer Causes Control 2008.
53. Aline Simen K, Tapio L, Joakim D, Matti H, Eija M, Steinar T, Linda Y, Matti L. Smoking is an independent risk factor for invasive cervical cancer: a population-based, longitudinal study in the Nordic Countries. Am J Epidemiol 2008.
54. Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006;51:303-311 (Pubitemid 43265813)
55. Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, Borner MM, Betticher DC. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003;21:2085-2093 (Pubitemid 46606356)
56. Itoh Y, Mizuki N, Shimada T, Azuma F, Itakura M, Kashiwase K, Kikkawa E, Kulski JK, Satake M, Inoko H. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 2005;57:717-729 (Pubitemid 41598618)
57. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48:27-33.
58. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-1638
59. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-309 (Pubitemid 33096456)